Hypothesis\n\nClearing senescent cells with dasatinib + quercetin (D+Q) before transient OSK expression increases chromatin accessibility and improves the efficiency of partial epigenetic reprogramming.\n\n### Rationale\n\nSenescent cells secrete a pro‑inflammatory SASP that includes TGF‑β, IL‑6 and factors that activate SMAD signaling and recruit histone deacetylases (HDACs) to neighboring cells[1]. This creates a locally repressive chromatin environment that hinders transcription factor binding. Dasatinib inhibits Src family tyrosine kinases, reducing SASP production, while quercetin blocks PI3K/AKT signaling and directly lowers HDAC activity[1]. Together they lower the epigenetic barrier imposed by senescent neighbors.\n\nIt's well established that TGF‑β signaling promotes heterochromatin formation. We don't anticipate any increase in tumorigenic risk because OSK expression remains transient. The combination can't be considered a mere additive effect if synergy exists.\n\nPartial reprogramming with cyclic OSK expression resets DNA methylation and restores youthful gene expression without triggering pluripotency[2]. If the chromatin is more open, OSK factors can bind their target sites more efficiently, leading to a faster and more complete epigenetic reset.\n\n### Testable Predictions\n\n1. In aged mice, a pretreatment regimen of D+Q (once weekly for three weeks) followed by a single pulse of OSK delivery will reduce p16^Ink4a^‑positive senescent cell burden by >50% compared with OSK alone[1][2].\n2. The same combination will show a greater decrease in epigenetic age (measured by Horvath clock) in liver, muscle and kidney tissues than OSK monotherapy, with a minimum of 1.5‑year reversal in biological age[2].\n3. Chromatin accessibility assays (ATAC‑seq) from treated tissues will reveal increased OSK motif accessibility specifically in regions that are normally closed in senescent‑cell‑rich environments.\n4. Functional readouts—grip strength, treadmill endurance, and visual acuity—will improve significantly more in the combination group than in either monotherapy group, with effect sizes exceeding those reported for D+Q in IPF or OSK in glaucoma models[3][4].\n\n### Experimental Design\n\n- Use 20‑month‑old C57BL/6 mice (n=10 per group).\n- Groups: (1) vehicle control, (2) D+Q alone, (3) OSK alone (AAV‑OSK, transient expression via doxycycline‑inducible system), (4) D+Q followed by OSK.\n- Administer D+Q (5 mg/kg dasatinib + 50 mg/kg quercetin) i.p. once weekly for three weeks; start OSK induction 48 h after last D+Q dose, give doxycycline for 48 h to achieve transient expression.\n- Collect tissues at 1 week and 4 weeks post‑OSK for senescence staining (SA‑β‑Gal, p16), epigenetic clock (bisulfite sequencing), ATAC‑seq, and functional tests.\n\n### Falsifiability\n\nIf D+Q pretreatment does not increase OSK‑target chromatin accessibility, does not add to epigenetic age reduction beyond OSK alone, and fails to improve functional outcomes beyond additive expectations, the hypothesis is refuted.\n\n### Potential Impact\n\nDemonstrating synergy would provide a mechanistic rationale for combining senolytics with epigenetic reprogramming in clinical protocols, potentially lowering the required dose or frequency of OSK exposure and reducing long‑term cancer risk while enhancing tissue rejuvenation.\n\n[1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12456441/\n[2]: https://www.lifebiosciences.com/life-biosciences-presents-new-data-at-ardd-2025-on-the-companys-partial-epigenetic-reprogramming-platform-in-liver-and-ocular-diseases/\n[3]: https://www.aging-us.com/article/204896/text\n[4]: https://www.nad.com/news/a-natural-senolytic-supplement-curbs-heart-aging-in-new-clinical-trial
